GLP-3 RT is an investigational triple-agonist peptide designed to simultaneously activate GLP-1, GIP, and Glucagon receptors. This unique multi-receptor activity has made GLP-3 RT one of the most studied next-generation metabolic research peptides in preclinical and early clinical development models.
It is researched primarily for its effects on energy balance, metabolic regulation, and adipose tissue signaling.
Scientific Background
GLP-3 RT is a synthetic 39-amino-acid peptide engineered to act as a potent agonist of:
GLP-1 receptor – involved in glucose regulation, appetite signaling, and gastric emptying
GIP receptor – associated with insulin release and metabolic sensitivity
Glucagon receptor – influences energy expenditure and fat mobilization
By engaging all three pathways simultaneously, GLP-3 represents a new class of triple-hormone receptor agonists.
Research Areas of Interest
All information below is strictly intended for laboratory, scientific, and in-vitro research discussion only.
1. Metabolic Regulation
GLP-3 RT is studied for its ability to influence:
Energy balance
Glucose handling
Insulin sensitivity
Hormonal signaling in metabolic tissues
2. Body-Weight Research Models
Due to its multi-receptor activity, research models evaluate potential effects on:
Appetite signaling
Energy expenditure
Lipolysis and fat mobilization
3. GLP-1 + GIP + Glucagon Synergy
GLP-3 RT’s triple-agonist mechanism allows researchers to assess:
Combined incretin activity
Crosstalk between glucagon and insulin pathways
Multi-pathway metabolic switching
4. Adipose & Liver Tissue Studies
Investigative models explore potential roles in:
Fatty-acid oxidation
Hepatic glucose output
Adipose tissue remodeling
5. Next-Generation Incretin Research
GLP-3 RT is part of a broader category of advanced incretin-based research peptides including:
GLP-2 (dual GLP-1/GIP agonist)
Cagrilintide (amylin analogue)
Semaglutide (GLP-1 agonist)
GLP-3 RT’s triple-agonist profile makes it a unique tool for studying combination hormone activity.
Molecular Profile
Peptide: GLP-3 RT
Type: GLP-1/GIP/Glucagon Triple-Receptor Agonist
Sequence Length: 39 amino acids (synthetic analogue)
Form: Lyophilized powder
Purity: ≥ 98% (HPLC tested)
Exact full amino-acid sequence is typically proprietary in pharmaceutical development and not publicly displayed by peptide vendors.
Storage & Stability
Store lyophilized peptide at –20°C
Protect from light, heat, and moisture
Reconstituted solutions should be handled using standard laboratory procedures
Each 3 mL vial is formulated with 10 mg of highly purified (>99%) lyophilized GLP-3 RT, produced in sterile environments that meet research-grade standards. Prime Peptides validates every batch through third-party laboratory testing to ensure exact molecular composition, stable peptide structure, and consistent results suitable for a wide range of experimental designs
